Stock Market 2025

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

AMD's AI Chip Roadmap Under Scrutiny: Wall Street Stays Bullish Despite Production Rumors

While reports surface of potential delays for AMD's next-generation MI450 AI accelerators, major analysts reaffirm bullish price targets, highlighting strong long-term demand and the stock's 100% surge over the past year.

Feb 2, 2026

Business

Beyond Bullion: As Precious Metals Soar, Rare Coins Emerge as a Contrarian Safe Haven for 2026

With gold and silver hitting record highs amid market turbulence, numismatic experts argue that certified rare coins offer a unique blend of tangible value, historical significance, and surprising liquidity for discerning investors.

Feb 2, 2026

Business

Beyond NVIDIA: How Broadcom and TSMC Are Cashing In on the AI Custom Chip Revolution

As tech giants design their own AI processors, Broadcom's design expertise and TSMC's manufacturing might are creating a lucrative second front in the semiconductor boom, diversifying the winners beyond the GPU market leader.

Feb 2, 2026

Business

Commodities Open February Under Broad Selling Pressure; Energy Leads Declines

Global commodity markets opened the new week and month deep in negative territory, with the energy sector plummeting an average of 7.3% and grains facing headwinds from shifting trade flows and seasonal pressures.

Feb 2, 2026

Business

Grail Seeks FDA Green Light for Pioneering Multi-Cancer Blood Test, Paving Way for Broader Insurance Coverage

The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.

Feb 2, 2026

Business

Beyond Survival: Eight Trends Redefining Small Business Success in 2026

A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.

Feb 2, 2026

Business

Taysha Gene Therapies Gains Momentum as Wells Fargo Raises Target on Rett Syndrome Program

Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.

Feb 2, 2026

Business

U.S. Launches $12 Billion 'Project Vault' to Counter China's Rare Earth Dominance

The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

Nova Ltd. (NVMI) Upgraded as Semiconductor Equipment Sector Shows Signs of Robust Recovery

Needham raises Nova Ltd. (NVMI) to Buy with a $500 price target, citing improving industry conditions and the company's strategic position in China's memory market. The upgrade follows a similar bullish move by Bank of America earlier in January.

Feb 2, 2026

Business

Vanguard Cuts Fees Again, Pushing Industry-Wide Average to Historic 0.06%

The $12 trillion asset manager founded by Jack Bogle announced another round of expense reductions across 53 funds, saving investors an estimated $600 million over two years and reinforcing its half-century mission of driving down costs for the everyday investor.

Feb 2, 2026

Business

Weekend Bitcoin Plunge Leaves CME Futures With a 7% Gap – Will History Repeat Itself?

A sharp weekend sell-off in Bitcoin's spot market has left a significant pricing gap on the CME's futures exchange, a phenomenon traders are watching closely for a potential rebound signal.

Feb 2, 2026

Business

Grubhub Bets Big on Super Bowl Debut: George Clooney Stars in Surreal Ad to Announce Fee-Free Orders

In a major Super Bowl play, Grubhub unveils a new 'No Fees' offer for large orders, backed by a bizarre ad directed by Yorgos Lanthimos and featuring George Clooney, aiming to reset its position in the competitive delivery market.

Feb 2, 2026

Business

Exodus Movement Maintains Debt-Free Stance as Product Suite Grows, Despite Analyst Target Cut

The cryptocurrency wallet provider Exodus Movement reports disciplined capital management with a debt-free balance sheet and 1.5 million monthly users, even as BTIG trims its price target citing cautious volume outlook.

Feb 2, 2026

Business

Goldman Sachs CEO Signals Strategic Hiring Slowdown Amid Efficiency Push

Goldman Sachs CEO David Solomon, while optimistic on global markets, forecasts a deliberate deceleration in talent acquisition for 2026 as the bank sharpens its focus on operational efficiency and strategic resource allocation.

Feb 2, 2026

Business

Apple Poised for Strongest iPhone Growth in Years as Holiday Sales Surge, Google AI Partnership Looms

Buoyed by robust demand for its premium iPhone 17 Pro models, Apple is projected to report its highest quarterly iPhone sales increase in over four years. Analysts spotlight a pivotal AI deal with Google's Gemini as a key future growth lever, even as the tech giant navigates supply chain cost pressures.

Feb 2, 2026

Business

GSK Returns Rights to Wave's Pioneering RNA Editing Therapy, Citing Strategic Focus Shift

In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.

Feb 2, 2026

Business

Vanguard Slashes Fees on Dozens of Funds, Intensifying Price War in Asset Management

The investment giant Vanguard has cut management fees on 53 of its mutual funds and ETFs, a move projected to save investors nearly $250 million in 2026 and marking the latest salvo in an industry-wide race to lower costs for everyday savers.

Feb 2, 2026

Business

Nvidia's AI Dominance and the $3 Trillion Data Center Boom: Why Analysts See Room to Run

As the AI infrastructure race accelerates, Nvidia's relentless innovation cycle and commanding market position point to sustained growth, with data center spending projected to reach trillions annually by 2030.

Feb 2, 2026